Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Patient-reported outcomes of avatrombopag for chronic immune thrombocytopenia: Interim analysis of the Phase 4 adopt study

Maria Eva Mingot, María Teresa Alvarez-Román, Maria Lozano et al. Nov 03, 2025 pp. 6237-6237 10.1182/blood-2025-6237

Abstract Introduction: Avatrombopag (AVA) is a thrombopoietin receptor agonist (TPO-RA) widely approved for the treatment of patients with c...

Identification of predictive protein signatures of treatment-free remission in patients with chronic myeloid leukaemia

Isla Nosratzadeh, Shaun Patterson, John Cole et al. Nov 03, 2025 pp. 1992-1992 10.1182/blood-2025-1992

Abstract Introduction: In the DESTINY trial (NCT01804985) bone marrow (BM) samples were taken from 160 patients with chronic myeloid leukaem...

Trends in chronic lymphocytic leukemia mortality among patients with pneumonia in the United States (1999–2024): A CDC wonder database analysis

Muhammad Shaheer Bin Faheem, Syed Tawassul Hassan, Shruthi Sridhar et al. Nov 03, 2025 pp. 8042-8042 10.1182/blood-2025-8042

Abstract INTRODUCTION: Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy among older adults, with pn...

Dose intensive regimen of CK0804 tregs in myelofibrosis

Lucia Masarova, Mehrdad Abedi, Naveen Pemmaraju et al. Nov 03, 2025 pp. 5602-5602 10.1182/blood-2025-5602

Abstract Background: Myelofibrosis (MF) is a clonal hematopoietic stem cell disorder marked by significant inflammation and immune deregulat...

Complement inhibition in pediatrics: Comprehensive infection analysis from a large pediatric single center

Sara Graciaa, Ronak Dave, Logan Pickett et al. Nov 03, 2025 pp. 1330-1330 10.1182/blood-2025-1330

Abstract Background Complement inhibition (Ci) has revolutionized outcomes in disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) a...

The dimorphism at the HLA-B leader and molecular HLA compatibility impact on haplo-HSCT: Experience of a single-center based on ptcy strategies

Rodrigo Gil-Manso, Francisco Javier Gil Etayo, Marta Fonseca-Santos et al. Nov 03, 2025 pp. 2471-2471 10.1182/blood-2025-2471

Abstract Introduction: The challenges of finding HLA-matched donors for hematopoietic stem cell transplantation (HSCT) has led to the increa...

Intravenous iron administration during sepsis: Outcomes, safety, and hemoglobin response

Lindsay Wilson, Jennifer Collins, Khwaja Omar et al. Nov 03, 2025 pp. 1129-1129 10.1182/blood-2025-1129

Abstract Background Sepsis is a life-threatening syndrome characterized by a dysregulated immune response and ensuing or...

Efficacy and safety of blinatumomab as frontline treatment for infant acute lymphoblastic leukemia

Jie Yang, Wei Lin, Jia Fan et al. Nov 03, 2025 pp. 6860-6860 10.1182/blood-2025-6860

Abstract Background Infant acute lymphoblastic leukemia (IALL) is highly aggressive with poor prognosis, representing a key focus and challe...

Longitudinal analysis of first and subsequent-line tyrosine kinase inhibitor use in chronic myeloid leukemia: A 16-year single-center experience

Moaath Mustafa Ali, Emily Zabor, Kamilla Abdurakhmanov et al. Nov 03, 2025 pp. 2012-2012 10.1182/blood-2025-2012

Abstract Background Tyrosine kinase inhibitors (TKIs) have significantly improved outcomes in chronic myeloid leukemia (CML), leading to pro...

Identification of dynamic markers for multiple myeloma in patients with MGUS and T2DM

Mei Wang, Yuan-Hung Kuan, Jr-Shin Li et al. Nov 03, 2025 pp. 5784-5784 10.1182/blood-2025-5784

Abstract Introduction: Multiple myeloma (MM) is a common, incurable blood malignancy. It is consistently preceded by a precursor condition m...

Clinical features and prognostic model for adenovirus infection following allogeneic hematopoietic stem cell transplantation: Insights from a Chinese cohort

Jiaxin Zhang, Jin Wu, Hai-Xia Fu et al. Nov 03, 2025 pp. 6056-6056 10.1182/blood-2025-6056

Abstract Introduction Adenovirus (AdV) infection is a potentially life-threatening complication following allogeneic hem...

Acquired hemophilia A associated with amlodipine use in a hypertensive patient: A case report

Mai Abouzeid, Mohamed Ghonim, Ahmed Elkalashy et al. Nov 03, 2025 pp. 6630-6630 10.1182/blood-2025-6630

Abstract Hemophilia is a bleeding disorder characterized by deficiency of factors within the coagulation cascade. Typically, hemophilia is a...

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Yongping Song, Zhenyu Li, Zunmin Zhu et al. Nov 03, 2025 pp. 5245-5245 10.1182/blood-2025-5245

Abstract Introduction Treating acute myeloid leukemia (AML), a diverse group of hematological cancers affecting bone marrow and blood, remai...

A rare case of high-risk M4 Acute Myeloid Leukemia with ETV6::ABL1 rearrangement in a young adult with preceding chronic idiopathic thrombocytopenia: Insights and implications

Mohamad Bakkar, Eman Al-Antary Nov 03, 2025 pp. 6938-6938 10.1182/blood-2025-6938

Abstract Background: ETV6::ABL1 rearrangement is exceptionally rare in acute myeloid leukemia (AML), particularly in ped...

Trends and disparities in myeloid leukemia related mortality in the United States from 1968 to 2016: CDC wonder analysis

Allahdad Khan, Sheikh Abdullah, Eaman Fatima et al. Nov 03, 2025 pp. 8191-8191 10.1182/blood-2025-8191

Abstract Background: Myeloid leukemia (ML), a heterogeneous group of hematologic malignancies, encompasses acute and chronic forms and remai...

Limited diagnostic utility of abdominal fat pad biopsy for systemic amyloidosis: A single institution's experience

Mark Oliver, Timothy Schmidt, David Yang Nov 03, 2025 pp. 2788-2788 10.1182/blood-2025-2788

Abstract Background: As a minimally invasive procedure, abdominal fat pad biopsy is commonly used as an initial diagnostic screening tool in...

Burden of comorbid conditions and hospital outcomes in sickle cell trait patients with atrial fibrillation: A retrospective nationwide analysis

Sangam Sangam, Sneha Singh, Pedro Arias-Sanchez et al. Nov 03, 2025 pp. 4371-4371 10.1182/blood-2025-4371

Abstract Background: Sickle cell trait (SCT) is linked to worse cardiovascular and renal outcomes. Increased prevalence of atrial fibrillati...

Assessment of prolonged thrombocytopenia after CD19 CAR-T therapy: Evidence for reduced production

Toral Shastri, Gerald Soff, Damian Green et al. Nov 03, 2025 pp. 4157-4157 10.1182/blood-2025-4157

Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has shown high response rates and lasting remissions in some patients...

Lachnospiraceae-mediated bile acid metabolism promotes ileal epithelial regeneration following graft-versus-host disease damage

Tomo Hayase, Achouak Achour, Rasoul Pourebrahim et al. Nov 03, 2025 pp. 162-162 10.1182/blood-2025-162

Abstract In allogeneic hematopoietic stem cell transplantation (allo-HSCT), complications such as graft-versus-host disease (GVHD) continue...

Patterns and clinical impacts of hematology electronic consults: A retrospective, single-center analysis

Shrinkhala Khanna, Aviv Liani, Clara Cabot et al. Nov 03, 2025 pp. 4384-4384 10.1182/blood-2025-4384

Abstract Background: With the several months wait for new patient appointments in hematology, many institutions have been exploring electron...

Apheresis blood processing with heparin improves stem cell collection outcomes for sickle cell gene therapy

David Justus, Carly Howard, Ellen Proeung et al. Nov 03, 2025 pp. 6096-6096 10.1182/blood-2025-6096

Abstract The expansion of gene therapy (GT) for sickle cell disease (SCD) has underscored the critical need to collect large numbers of stem...

Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia

Andrius Zucenka, Milda Mikalonyte, Tautvile Smalinskaite et al. Nov 03, 2025 pp. 1679-1679 10.1182/blood-2025-1679

Abstract BACKGROUND Triplet therapies with hypomethylating agents (HMA), venetoclax, and second-generation FLT3 inhibitors have demonstrated...

Subclinical cardiac changes following CPX-351 induction in adults with favorable/intermediate-risk AML

Chezi Ganzel, Avraham Frisch, Ofir Wolach et al. Nov 03, 2025 pp. 5239-5239 10.1182/blood-2025-5239

Abstract Background: CPX-351 is a liposomal formulation of daunorubicin and cytarabine, approved for the treatment of newly diagnosed therap...

Cost effectiveness of in-house HIT screening testing in community based hospital

Jankikeerthika Dharmarpandi, Nam Huynh, Omar Mahmood et al. Nov 03, 2025 pp. 4380-4380 10.1182/blood-2025-4380

Abstract Background Heparin-induced thrombocytopenia type II (HIT) is a rare but potentially life-threatening immune-mediated complication e...

A combination strategy of inotuzumab ozogamicin (InO) and BCL-2 family inhibitors prevents the emergence of PGP+ ino-resistant MRD in B-cell acute lymphoblastic leukemia

Anna Akaogi, Kenichi Ishiyama, Toshio Kitawaki et al. Nov 03, 2025 pp. 1527-1527 10.1182/blood-2025-1527

Abstract Background: Inotuzumab ozogamicin (InO) achieves a complete remission (CR) rate of over 60-80% in patients with relapsed/refractory...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page